-
Jefferies Maintains Buy on Valeant Pharmaceuticals (VRX)
Wednesday, February 23, 2011 - 11:38am | 89Jefferies is out with its report today on Valeant Pharmaceuticals (NYSE: VRX), maintaining Buy. In a note to clients, Jefferies writes, "VRX has been the top performing Spec Pharma stock in 2011 (~40% YTD), but with a high degree of confidence in management's ability to execute on its growth...
-
Jefferies Sees No Value Destruction To Forest Laboratories
Wednesday, February 23, 2011 - 10:33am | 181Jefferies & Company has published a research report on Forest Laboratories (NYSE: FRX) as Jefferies believes that the company will experience no value destruction to shares despite its deep late-stage pipeline operations. In the report, Jefferies writes "Viibryd, CLDA's (NASDAQ: $31.21, NC)...
-
Citi Downgrades Forest Laboratories To Hold, Lowers PT To $35 (FRX)
Wednesday, February 23, 2011 - 10:31am | 105Citi downgraded Forest Laboratories (NYSE: FRX) from Buy to Hold and lowered its Forest Laboratories price target from $39 to $35 in a research report published today. In the report, Citi states, "FRX expects heavy dilution from the deal in the near-term. In addition, we see downside risk from a...
-
Oppenheimer Reiterates Its Underperform Rating On CADX
Wednesday, February 23, 2011 - 10:26am | 112Oppenheimer is reiterating its Underperform rating on shares of Cadence Pharmaceuticals, Inc. (NASDAQ: CADX) on expectations for a softer than expected OFIRMEV launch. “We anticipate consensus revenues for OFIRMEV will come down over 2011, pressuring shares,” Oppenheimer writes. “While CPIX's...
-
Oppenheimer Adjusts FRX Estimates Following CLDA Acquisition Announcement
Wednesday, February 23, 2011 - 9:52am | 191On 2/22, Forest Laboratories, Inc. (NYSE: FRX) announced an agreement to acquire Clinical Data, Inc. (NASDAQ: CLDA) with the transaction expected complete ~2Q11. “FRX will pay $30.00/sh plus up to $6.00/sh related to Viibryd commercial milestones,” Oppenheimer writes. “At ~2.0x our Viibryd peak...
-
Benzinga's Top Downgrades (EXPD, NFLX, FRX, AN)
Wednesday, February 23, 2011 - 9:26am | 132Expeditors International of Washington Inc (NASDAQ: EXPD) was downgraded by Credit Suisse from "outperform" to "neutral." EXPD's shares closed at $49.04 yesterday. EXPD's PEG ratio is 2.37. Needham downgraded Netflix Inc (NASDAQ: NFLX) from “hold” to “underperform.” NFLX' stock closed at $221.60...
-
Adolor Reports Q4 EPS of $(0.59) vs. $(0.10)
Wednesday, February 23, 2011 - 9:09am | 51Adolor Corporation (NasdaqGM: ADLR) today reported a net loss of $27.3 million, or $(0.59) per basic and diluted share, for the year ended December 31, 2010, compared to a net loss of $47.9 million, or $(1.03) per basic and diluted share, for the year ended December 31, 2009. Total revenues, net...
-
Citigroup Downgrades Forest Laboratories To Hold, PT To $35
Wednesday, February 23, 2011 - 9:08am | 27Citigroup has downgraded Forest Laboratories (NYSE: FRX) from Buy to Hold and has lowered the price target from $39 to $35.
-
Mad Money Lightning Round: Cramer Advises Investors To Buy Apache (BMY, AAPL, APA, IBN, FCX, BHP)
Wednesday, February 23, 2011 - 3:58am | 184On CNBC's Mad Money, Jim Cramer said during the Lightning Round that Bristol-Myers Squibb (NYSE: BMY) is “not doing anything.” He added, “They don't have a good pipeline. In the end there's little growth." For Apple (NASDAQ: AAPL), he said, "Expect that you'll have to buy more. It could have...
-
Fast Money Picks For February 23rd (MTL, FRO, TSL, ABT, QCOM)
Tuesday, February 22, 2011 - 8:18pm | 205On CNBC's Fast Money, Tim Seymour said that he would short Mechel OAO (ADR) (NYSE: MTL) tomorrow. Mechel OAO (ADR) (MTL) dropped 5.39% today, and closed at $29.69. Brian Kelly is a buyer of Frontline Ltd. (USA) (NYSE: FRO), because the floating storage is kicking up. Frontline Ltd. (USA) (FRO) fell...
-
Stocks on the Move (TGB),(ELOS),(CPD),(GLUU)
Tuesday, February 22, 2011 - 3:54pm | 36Stocks on the Move (TGB),(ELOS),(CPD),(GLUU)...
-
U.S. Supreme Court Decision Protects Manufacturers of FDA-approved Childhood Vaccines
Tuesday, February 22, 2011 - 2:51pm | 77Today, in a 6-2 decision, the U.S. Supreme Court affirmed the ruling of the U.S. Court of Appeals for the Third Circuit in favor of Pfizer's (NYSE: PFE) subsidiary Wyeth, in Bruesewitz v. Wyeth. The Third Circuit determined that the National Childhood Vaccine Injury Act prevents civil suits...
-
Amarin Corp. Sitting At Session Lows (AMRN)
Tuesday, February 22, 2011 - 12:01pm | 91Amarin Corp. (NASDAQ: AMRN) are having a very poor trading session and are currently sitting at their lows for the day. The stock has lost 5.25% to $8.39. There does not appear to be any significant news out that is driving the activity in the stock. Amarin Corporation plc (Amarin) is a clinical-...
-
Downside Purchased on Forest Laboratories (FRX)
Tuesday, February 22, 2011 - 11:33am | 152Shares of Forest Laboratories (NYSE: FRX) are lower on the session by 4.11%, currently trading at $32.92. The stock has been moving largely higher over the past six months and is currently trading above the 50-day and 200-day moving averages. Options traders are buying puts on the name today. A...
-
Caraco Announces Merger Agreement with Sun Pharma at $5.25 per Share
Tuesday, February 22, 2011 - 10:05am | 209Caraco Pharmaceutical Laboratories, Ltd. (NYSE: CPD) announced that on February 21, 2011 it entered into a merger agreement with Sun Pharmaceutical Industries Limited, Sun Pharma Global, Inc, a wholly-owned subsidiary of Sun Pharma organized under the laws of the British Virgin Islands and a newly-...